Extended Data Fig. 2: MPR in patients with stage III N2 and non-N2 NSCLC. | Nature Cancer

Extended Data Fig. 2: MPR in patients with stage III N2 and non-N2 NSCLC.

From: Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis

Extended Data Fig. 2

Patients with (a) N2 or non-N2 NSCLC and (b) single-station or multi-station N2 status. a–l95% CI: a6.9–29.8; b20.5–40.2; c5.5–19.5; d8.5–36.9; e27.2–51.0; f7.5–26.1; g13.2–44.1; h28.7–55.9; i5.1–23.7; j16.2–51.5; k35.8–66.3; l6.5–29.5. mThe N2 subcategory was not reported in 1 patient in the nivolumab arm. n − 2.0–26.1; o13.6–36.6; p4.3–23.0; q − 4.0–31.8; r18.2–46.6; s6.2–32.0; t10.3–49.6; u24.5–60.9; v3.0–25.4; w15.0–60.1; x32.8–74.4; y3.9–31.7. The 95% CIs were determined for each treatment arm using the Clopper-Pearson method. An estimate of the unstratified difference in MPR rates and the corresponding 95% CI were calculated using the Newcombe method. CI, confidence interval; MPR, major pathological response; NSCLC, non-small cell lung cancer.

Source data

Back to article page